Avalo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTX research report →
About the company
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
- CEO
- Garry A. Neil
- IPO
- 2015
- Employees
- 23
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $212.78M
- P/E
- -4.47
- P/S
- 3606.46
- P/B
- 5.54
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
- Gross Margin
- -17996.61%
- Op Margin
- -134164.41%
- Net Margin
- -143627.12%
- ROE
- -97.55%
- ROIC
- -89.33%
- Revenue
- $59.00K · -86.62%
- Net Income
- $-78,259,000 · -122.78%
- EPS
- $-5.84 · -35.19%
- Op Income
- $-72,925,000
- FCF YoY
- -4.90%
- 52W High
- $24.27
- 52W Low
- $4.61
- 50D MA
- $16.18
- 200D MA
- $15.89
- Beta
- 0.82
- Avg Volume
- 1.95M
Get TickerSpark's AI analysis on AVTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Doyle Mittie | other | 2,875 |
| Jun 30, 26 | Doyle Mittie | other | 1,779 |
| Jun 30, 26 | Doyle Mittie | other | 1,779 |
| Jun 30, 26 | Doyle Mittie | other | 2,875 |
| Jun 30, 26 | Doyle Mittie | sell | 4,654 |
| Jun 30, 26 | Philip Ron M | other | 69 |
| Jun 30, 26 | Lind Kevin Robert | other | 1,105 |
| Jun 30, 26 | Jain Rita | other | 1,080 |
| Jun 23, 26 | Doyle Mittie | other | 1,450 |
| Jun 23, 26 | Doyle Mittie | other | 1,450 |
Our AVTX coverage
Recent articles, reports, and earnings notes.
No research on AVTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTX report →Similar companies
Peers in the same neighborhood.